BY MARKETWIRE
-
Novo’s weight loss drug approved by US cardiologists
Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are pointed out in brand-new standards from United States cardiologists as medicines to take into consideration for avoid…
-
Zealand Pharma stock down 45% this year: Hit by publicity drought
This is the analysis of experts at William Blair.
-
EU increasingly resigned to 10% mutual tariff with the US
Nonetheless, EU mediators are still promoting the price to be less than 10%.
-
Bavarian Nordic’s USD 160m voucher sale indicates rising value
According to media records, the rate rises result from unpredictability concerning the variety of top priority evaluation coupons to be provided by the United States wellness autho…
-
Novo Nordisk wins in Texas: Compounders may no longer make Wegovy and Ozempic
This comes as a United States court has actually supported the FDA’s choice to eliminate Semaglutide from the medication lack listing.
-
Zealand Pharma presents strong weight loss data with drug candidate
This is the 2nd component of the biotech firm’s stage Ib research study with the medicine dapiglutide, which is based upon the GLP-1 and GLP-2 representatives.
-
Trump to launch tariffs on pharmaceuticals “very soon”
The declaration from the United States head of state was available in relationship to the G7 top on Tuesday.
-
Eli Lilly expands Zepbound options for patients without health insurance
Both greatest dosages of the fat burning medicine Zepbound will certainly currently be offered to United States people without medical insurance.
-
Media: Eli Lilly nears billion-dollar acquisition of gene editing biotech
Vigor Rehabs is establishing a gene-editing treatment to deal with poor cholesterol.
-
US biotech stock plummets after therapy patient dies
This is the 2nd time a person has actually passed away throughout therapy with the business’s genetics treatment for Duchenne muscle dystrophy.